Overview
Folate-NHS Ester (Fo-NHS) is a chemically modified derivative of folic acid, designed to facilitate covalent bonding with amino groups in biomolecules. Its NHS ester group reacts efficiently with primary amines, making it indispensable in bioconjugation workflows. The compound retains the targeting capability of folate, which binds to folate receptors overexpressed in many cancer cells. This reagent is particularly valued in pharmaceutical and biomedical research for its ability to create stable folate-linked conjugates. Its applications range from antibody labeling to nanoparticle functionalization, often serving as a bridge between targeting ligands and therapeutic agents.
Physical and Chemical Properties
Fo-NHS typically presents as a yellow-orange crystalline powder with moderate stability under dry, cold conditions. The NHS ester moiety is highly reactive toward nucleophiles, especially in aqueous or polar aprotic solvents like DMSO. This reactivity necessitates careful handling to prevent hydrolysis, which deactivates the compound. The folate component provides water solubility to the conjugate, while the aromatic pteridine ring contributes to UV absorbance at 280-365 nm, useful for quantification. The ester linkage formed during conjugation is stable under physiological conditions, ensuring long-term performance in biological systems.
Main Applications
In targeted cancer therapies, Fo-NHS conjugates drugs to folate molecules, directing them to tumor cells with high folate receptor expression. This approach minimizes systemic toxicity while enhancing therapeutic efficacy. The compound is also integral to ELISA development, where it links folate to detection antibodies or enzymes. Researchers employ Fo-NHS in nanotechnology to functionalize liposomes and polymeric nanoparticles for diagnostic imaging. Additionally, it’s used to create folate-affinity columns for protein purification. Recent advances explore its role in dual-targeting systems combining folate with other targeting moieties.
Safety and Storage
As a reactive compound, Fo-NHS requires strict handling protocols. Always use nitrile gloves and safety goggles in ventilated areas to avoid inhalation or skin contact. Spills should be neutralized with dilute ammonia solution before disposal as hazardous organic waste. For long-term stability, store the lyophilized powder at -20°C in airtight containers with desiccant packs. Aliquot reconstituted solutions to avoid freeze-thaw cycles, and use within 24 hours when dissolved in DMSO. Degradation manifests as color darkening and reduced conjugation efficiency.
B2B Procurement Guide
When sourcing Fo-NHS, prioritize suppliers providing NMR and HPLC purity certificates (≥95%). Request mass spectrometry data to confirm molecular identity, and insist on batch-specific COAs. Bulk buyers (100g+) may negotiate 15-30% discounts, but verify scalable synthesis capabilities. Lead times vary from 2-6 weeks depending on customization needs. For GMP-grade material (required for clinical applications), expect 3-6 month validation processes and 200-300% price premiums. Consider suppliers offering technical support for conjugation optimization, particularly for novel applications like ADC development.